Armata Pharmaceuticals, Inc. · AMEX:ARMP
Armata Pharmaceuticals — Investor Presentation (January 2022)
21 slides from Armata Pharmaceuticals's investor presentation, Jan 5, 2022
Slide 1: Armata Pharmaceuticals January 2022 Investor Presentation
Brian Varnum, Chief Executive Officer Steve Martin, Chief Financial Officer January 5, 2022 NYSE American: ARMP
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward -
Slide 3: Investment Highlights
3 Investment Highlights Phage cocktails targeting acute and chronic infections ▪ P. aeruginosa product candidates for respiratory infections ▪ Cystic fibrosis: First multi - center randomized trial ▪ Non - cystic fibrosis bronchiectasis ▪ Hospitalized pneumonia ▪ S. aureus phage product candidate ▪
Slide 4: Phage: Novel Biologic, MOA Distinct from Antibiotics
4 Phage: Novel Biologic, MOA Distinct from Antibiotics Rapidly Bactericidal, Natural Predator, Amenable to Engineering for Improved Functionality ▪ The most ubiquitous organisms on Earth ▪ Bacteria specific, including MDR strains ▪ Prior history as therapeutic agent – Antibiotics displaced phage use
Slide 5: Armata Benefits from Long History of Phage Development
5 Armata Benefits from Long History of Phage Development Pseudomonas aeruginosa ▪ >600 primary phage isolates; >230 with host range data; >270 sequenced phage ▪ >2,000 bacterial isolates Staphylococcus aureus ▪ >60 primary phage isolates; 11 phages screened for biocompatibility ▪ ~1,000 bacterial is
Slide 6: Armata's Capabilities and Operational Overview
6 Armata’s Capabilities and Operational Overview Purposely Built for Phage Product Development, Bench to Clinic Discovery • Phage libraries • Pathogen libraries • Synthetic biologists with phage engineering expertise • Computational biology team Preclinical Development • Well - equipped BSL2 labs •
Slide 7: Clinical Pipeline
7 Clinical Pipeline Program Discovery Preclinical IND - Enabling Phase 1b/2a Partner Pseudomonas aeruginosa Respiratory Infections Staphylococcus aureus CF Bacteremia US DoD US Department of Defense (Naval Medical Research Center, US Army Medical Research Acquisition Activity, Defense Health Agency
Slide 8: Pseudomonas aeruginosa Program
Cystic Fibrosis Non - CF Bronchiectasis Pneumonia Pseudomonas aeruginosa Program
Slide 9: Robust Discovery Engine Yields Optimal Cocktails
9 Robust Discovery Engine Yields Optimal Cocktails Phage Products Tailored for Pseudomonas respiratory Infections Clinical Isolate Collection Phage Screening Genomic Analysis O - antigen Indication Host Sensitivity Phage AP - PA02 AP - PA03 Genus Receptor 3 - phage 5 - phage ARPA0003 CF CF, NCFB 1 L
Slide 10: Optimized AP-PA02 Improves Cocktail for CF and NCFB
10 ▪ Two new phage genera added ▪ Coverage of at least 90% of CF clinical isolates ▪ Improved potency in vitro and in vivo ▪ Entering ongoing SWARM - P.a. study (MAD cohort) ▪ Advancing into Phase 2 trial in NCFB Optimized AP - PA02 Improves Cocktail for CF and NCFB In Vivo Activity 0 50 100 0 50 10
Slide 11: Pseudomonas aeruginosa: Respiratory Opportunity
11 Pseudomonas aeruginosa : Respiratory Opportunity Cystic Fibrosis ▪ Chronic P.a. infections occur in 55% of CF patients by age 25 • Strongly associated with lung decline, hospitalizations, and mortality ▪ 32% of patients in the Cf Foundation Registry infected with P.a. • ~ 13% infected with MDR P.
Slide 12: Staphylococcus aureus Program
Staphylococcus aureus Program Complicated Bacteremia Prosthetic Joint Infection
Slide 13: Medical Opportunity: MRSA A Serious Threat
13 Medical Opportunity Methicillin - Resistant S. aureus (MRSA): A Serious Threat 1 ▪ 323,700 new cases in hospitalized patients ▪ 10,600 deaths ▪ $1.7 billion of attributable healthcare costs First indication: S. aureus bacteremia (SAB) 2 ▪ S. aureus is the most commonly identified pathogen in hosp
Slide 14: AP-SA02: Phage Product Targeting S. aureus
14 AP - SA02: Phage Product Targeting S. aureus Robust Therapeutic Attributes ▪ Host range coverage of >90% across clinical isolates tested ▪ Robust potency against drug - resistant isolates, including MRSA, VISA, VRSA ▪ Penetrates pre - existing biofilms ▪ Maintains activity in presence of current
Slide 15: AP-SA02: Clinical Outline
15 AP - SA02: Clinical Outline $15M in Nondilutive Funding from US DoD to Support Phase 1b/2a Bacteremia Study Phase 1b/2a Follow - on study 2022 Regulatory Filing Patient population: Complicated bacteremia stratified for MRSA Route of administration: I.V. as adjunct to best available therapy Goals:
Slide 16: Corporate Summary
Corporate Summary
Slide 17: Strong Global IP Position Through Pending and Issued Patents
17 Strong Global IP Position Through Pending and Issued Patents 15 Patent Families, Long - Life Patents, Patents Granted in all Major Jurisdictions Expiration dates through 2041 Armata’s patents and applications cover: ▪ Therapeutic phage cocktails (Staphylococcus and Pseudomonas) and uses thereof ▪
Slide 18: Recent Accomplishments and Anticipated Milestones
18 Recent Accomplishments and Anticipated Milestones Pseudomonas phage respiratory programs ▪ Optimized AP - PA02 and advanced into ongoing SWARM - P.a. CF study ▪ Positioned to obtain topline SWARM - P.a. data in 2022 ▪ Obtain regulatory approval to initiate non - CF bronchiectasis Phase 2 study in
Slide 19: Leadership and Board of Directors
19 Leadership and Board of Directors Diverse Public Company Drug Development Expertise Robin Kramer Joseph Patti, PhD Sarah Schlesinger, MD Todd Patrick Todd Peterson, PhD Brian Varnum, PhD Steve Martin CFO Mina Pastagia, MD SVP, Clinical Development Duane Morris VP, Operations Management Board of D
Slide 20: Funding and Capitalization
20 Cash Position ▪ $12.1 million at September 30, 2021 ▪ October 2021: Executed $7M private placement of common stock with two investors - Cystic Fibrosis Foundation and a subsidiary of Innoviva , Inc. ▪ Q1 2021: Executed $20M private placement of common stock and warrants with a subsidiary of Innov
Slide 21: Armata Pharmaceuticals
PHARMACEUTICALS PURPOSEFUL ¢ PRECISE # POWERFUL __-
Armata Pharmaceuticals — Investor Presentation (January 2022) on 6ix